Knee Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Knee Osteoarthritis Drugs Market Introduction and Overview

According to SPER market research, 'Global Knee Osteoarthritis Drugs Market Size- By Drug Type, By Route of Administration, By Age Group- Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Knee Osteoarthritis Drugs Market is predicted to reach 15.3 billion by 2034 with a CAGR of 8.24%.

The degeneration of cartilage in osteoarthritis of the knee results in pain, stiffness, swelling, and restricted knee mobility. It is usually more common in older adults, but it can also strike younger people due to trauma, obesity, or genetic predisposition. The illness may have a significant impact on daily activities and lives. Treatment primarily aims to control symptoms and slow the progression of the illness through the use of medications such as analgesics, corticosteroids, nonsteroidal anti-inflammatory drugs, and new disease-modifying therapies.

Restraints: There are several challenges facing the knee osteoarthritis drug market that could limit its growth. High treatment costs, particularly for injectables and advanced therapies, may make treatment inaccessible to patients. Side effects and safety concerns associated with long-term use of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain analgesics may reduce patient adherence. When existing treatments fail to halt the progression of their diseases, some patients resort to surgery.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Drug Type, By Route of Administration, By Age Group

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Anika Therapeutics, Avanos, Biotech Healthcare, Bioventus, Ferring Pharmaceuticals, Fidia Pharma, GlaxoSmithKline (GSK), Haleon, Kenvue, Organon LLC, Pacira Pharmaceuticals, Pfizer, Premier Surgical, Sanofi, Stellar Pharmaceuticals.

Global Knee Osteoarthritis Drugs Market Segmentation:

By Drug Type: Based on the Drug type, Global Knee Osteoarthritis Drugs Market is segmented as: Non-steroidal anti-inflammatory drugs (NSAIDs), Corticosteroids, Viscosupplementation, Analgesics, Other drug types.

By Route of Administration: Based on the Route of Administration, Global Knee Osteoarthritis Drugs Market is segmented as; Oral, Parenteral, Topical

By Age Group: Based on the Age Group, Global Knee Osteoarthritis Drugs Market is segmented as; 18 a€" 44,45 a€"64, and Above 65.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25315

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Knee Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Knee Osteoarthritis Drugs Market

7. Global Knee Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034

7.1. Non-steroidal anti-inflammatory drugs (NSAIDs)
7.2. Corticosteroids
7.3. Viscosupplementation
7.4. Analgesics
7.5. Other drug types

8. Global Knee Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1. Oral
8.2. Parenteral
8.3. Topical

9. Global Knee Osteoarthritis Drugs Market, By Age Group (USD Million) 2021-2034

9.1. 18 - 44
9.2. 45 - 64
9.3. Above 65

10. Global Knee Osteoarthritis Drugs Market, (USD Million) 2021-2034

10.1. Global Knee Osteoarthritis Drugs Market Size and Market Share

11. Global Knee Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Anika Therapeutics
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Avanos
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Biotech Healthcare
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Bioventus
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Ferring Pharmaceuticals
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Fidia Pharma
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. GlaxoSmithKline
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Haleon
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Kenvue
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Organon LLC
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Pacira Pharmaceuticals
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments
12.12. Pfizer
- 12.12.1. Company details
- 12.12.2. Financial outlook
- 12.12.3. Product summary
- 12.12.4. Recent developments
12.13. Premier Surgical
- 12.13.1. Company details
- 12.13.2. Financial outlook
- 12.13.3. Product summary
- 12.13.4. Recent developments
12.14. Sanofi
- 12.14.1. Company details
- 12.14.2. Financial outlook
- 12.14.3. Product summary
- 12.14.4. Recent developments
12.15. Stellar Pharmaceuticals
- 12.15.1. Company details
- 12.15.2. Financial outlook
- 12.15.3. Product summary
- 12.15.4. Recent developments
12.16. Others